Moreover, each tumor stage also has high expression, at the same time, the correlation between SLC2A5 expression and prognosis based on different clinical characteristics indicates that SLC2A5 may be a potential independent biomarker for LUAD prognosis. This evidence concerns the gene SLC2A5 and neoplasm.